Compare HCSG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCSG | CSTL |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 722.8M |
| IPO Year | 1994 | 2019 |
| Metric | HCSG | CSTL |
|---|---|---|
| Price | $21.49 | $36.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $22.67 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 487.9K | 282.2K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.83 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,837,173,000.00 | $344,229,000.00 |
| Revenue This Year | $7.39 | $2.42 |
| Revenue Next Year | $5.22 | $12.69 |
| P/E Ratio | $31.91 | ★ N/A |
| Revenue Growth | ★ 7.08 | 3.66 |
| 52 Week Low | $15.26 | $17.72 |
| 52 Week High | $25.75 | $44.28 |
| Indicator | HCSG | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 69.04 |
| Support Level | $21.00 | $22.88 |
| Resistance Level | $22.39 | $42.03 |
| Average True Range (ATR) | 0.52 | 1.36 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 43.71 | 78.25 |
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company manages and evaluates its operations in two reportable segments: Environmental Services segment includes housekeeping, management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services, linen and other services; and Dietary Segment includes dietary department services, food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America. The Environmental Services segment derives maximum revenue.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.